A novel membrane-based anti-diabetic action of atorvastatin.
A novel membrane-based anti-diabetic action of atorvastatin.
复制标题
阿托伐他汀的一种新型基于膜的抗糖尿病作用。
DOI：
10.1016/j.bbrc.2008.05.095
复制
发表时间：
2008
影响因子：
3.1
通讯作者：
Elmendorf,JeffreyS
中科院分区：
文献类型：
--
作者：
Horvath,EmilyM;Tackett,Lixuan;Elmendorf,JeffreyS
We recently found that chromium picolinate (CrPic), a nutritional supplement thought to improve insulin sensitivity in individuals with impaired glucose tolerance, enhances insulin action by lowering plasma membrane (PM) cholesterol. Recent in vivo studies suggest that cholesterol-lowering statin drugs benefit insulin sensitivity in insulin-resistant patients, yet a mechanism is unknown. We report here that atorvastatin (ATV) diminished PM cholesterol by 22% (P<0.05) in 3T3-L1 adipocytes. As documented for CrPic, this small reduction in PM cholesterol enhanced insulin action. Replenishment of cholesterol mitigated the positive effects of ATV on insulin sensitivity. Co-treatment with CrPic and ATV did not amplify the extent of PM cholesterol loss or insulin sensitivity gain. In addition, analyses of insulin signal transduction suggest a non-signaling basis of both therapies. Our data reveal an unappreciated beneficial non-hepatic effect of statin action and highlight a novel mechanistic similarity between two recently recognized therapies of impaired glucose tolerance.
